SCBIO innovation partner GCMI names new CEO see more
Sherry Farrugia has been selected by the Global Center for Medical Innovation (GCMI) board of directors as the organization’s permanent CEO, effective April 1, 2021. Farrugia had been serving as interim CEO for GCMI, a Georgia Tech affiliate, since September 2020.
“We are so pleased to congratulate Sherry as she joins GCMI in this permanent capacity,” said Chaouki T. Abdallah, Georgia Tech’s executive vice president for Research. “She was a steadfast advocate, innovator, and leader in her time at Tech and I know she will bring that same dedication to the important, transformational work of GCMI.”
Farrugia came to GCMI from the Children’s Healthcare of Atlanta Pediatric Technology Center at Georgia Tech, where she served as chief operating and strategy officer for 10 years, focusing on accelerating innovation for pediatrics. During that time, Farrugia worked with GCMI on numerous projects. Recently, she played a key part in GCMI’s success supplying frontline healthcare workers with personal protective equipment during the pandemic.
“Sherry Farrugia is nationally recognized for her work in advancing translational medical research, and we are excited that she will continue with GCMI as permanent CEO,” said Bob Crutchfield, chair of the GCMI board of directors and CEO of TeleHealth Solution. “Her visionary leadership, strong community ties, and knowledge of the commercialization ecosystem and medical device strategy and development have been great assets to GCMI thus far and will be instrumental in our path forward.”
Recently, Farrugia was named to the board of directors for the Medical University of South Carolina Foundation for Research Development. She is currently an advisory board member of Atlanta Ronald McDonald House Charities, on the board of directors of the International Society of Pediatric Innovation, and a member of the Southeast Life Sciences Women@SLS advisory board.
“Sherry brings over 30 years’ experience in the healthcare innovation industry,” said Devesh Ranjan, Georgia Tech’s interim vice president for Interdisciplinary Research and Ring Family Chair and professor in the George W. Woodruff School of Mechanical Engineering. “Her knowledge and experience are invaluable, and I know she will serve the role well.”
In 2018, Farrugia received the Women in Technology Woman of the Year Award, and she was honored by Georgia Bio for three consecutive years for her work in supporting the life sciences.
“GCMI’s mission and history of working with startups, clinicians, and universities to bring innovative medical products to the world is perfectly aligned with my passion for supporting translational research in the healthcare space,” Farrugia said. “I am so pleased to accept the position as GCMI’s permanent CEO and to continue the important work to accelerate the development, testing, training, and commercialization of life-changing technologies.”
MUSC Foundation for Research Development holds Vournakis NAI Induction Ceremony and Adm. Albert Baciocco Innovator of the Year ReceptionMUSC FRD honors innovators, patent recipients at virtual gala... see more
Congratulations to all of the honorees from the recent John N. Vournakis NAI Induction Ceremony and Annual Adm. Albert J. Baciocco Innovator of the Year Reception. Learn about teh honorees and this highly anticipated annual event right here!
KIYATEC Advancing Functional Ex Vivo 3D Cell Culture Models that Reveal Response Dynamics to Immuno-Oncology DrugsKey evidence to be presented at AACR 2020 see more
KIYATEC, Inc. today announced that it will present data at the 2020 American Association for Cancer Research (AACR) Annual Meeting, June 22-24, revealing how its 3D cell culture models characterize ex vivo tumor response and immunoreactivity to immune checkpoint inhibitors (i.e. PD-1, PD-L1 inhibitors) in solid tumors. These emerging capabilities address a significant unmet need in both preclinical drug development and clinical decision-making in oncology.
PD-1/L1 inhibitors have experienced meteoric growth over the last decade, offering hope to hundreds of thousands of cancer patients every year in the US alone. However, typically no more than 25-30% of eligible cancer patients who receive PD-1/L1 inhibitors actually respond to them. Given that the direct costs associated with PD-1/L1 therapy can run into the hundreds of thousands of dollars per patient, KIYATEC believes that pre-treatment, patient-specific PD-1/L1 response prediction could one day offer clinicians, patients and payers a more objective basis for determining PD-1/L1 inhibitor patient eligibility vs. today’s commonly used population-based biomarkers.
Evidence presented by KIYATEC at AACR 2020 will highlight findings of the company’s ability to detect dose-dependent response to checkpoint blockade and corresponding correlation with immune cell activation in high-throughput ex vivo 3D tumor spheroid models. KIYATEC believes these recent advances may represent key building blocks toward the eventual development and validation of clinical assays capable of accurate pre-treatment, patient-specific prediction of response to immuno-oncology drugs.
“We’re constantly innovating and expanding the capabilities of our 3D cell culture technologies to reduce the cost and risk of preclinical drug development for our immuno-oncology customers,” said Matthew Gevaert, CEO of KIYATEC. “As we continue to make these advances in immuno-oncology drug response on higher-throughput platforms, we can begin to envision a time when such capability would inform clinical decision-making for cancer patients as well.”
KIYATEC’s poster presentations at AACR 2020 are as follows:
- Abstract: 7397 / Poster: 315 / Session: 3D & Tissue Recombinant Models / June 22-24
Title: PARP inhibition in combination with pembrolizumab enhances cytotoxicity in ovarian cancer patient-derived 3D spheroids
- Abstract: 7132 / Poster: 2244 / Session: Immune Checkpoints 2 / June 22-24
About KIYATEC, Inc.
KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit www.kiyatec.com.
Clemson, Prisma health professionals working to develop early cancer screening test see more
When her younger brother was diagnosed with cancer, Clemson bioengineering professor Terri Bruce re solved to tap her knowledge of human cells to find a way to help others suffering from the dis ease. After devouring all the scientific literature she could, she chose to focus on developing a screening test to detect the disease in its earliest stages when it has a better chance of being cured.
“It was a time in my life when I felt helpless,” she told The Greenville News.
“And I felt there’s got to be something I can do — even if I can’t help Greg — to help other people.”
Because he suffered from brain cancer, she looked to another form of the disease that wasn’t as emotionally entangled but had no early screening tests. She decided on ovarian cancer.
Now Bruce and her research team are on the brink of a test that they believe could be a screening tool — not only for ovarian cancer, but other cancers too.
“The hope,” she said, “is to ... catch this deadly cancer much earlier and give women a fighting chance.”
Ovarian cancer will strike 22,530 women this year, according to the American Cancer Society, and about 14,000 will die of the disease.
But only about one in five cases is discovered early because there are no reliable screening tests, the society reports.
A late diagnosis reduces survival. And because the symptoms are so vague, about three quarters of all women are diagnosed at a late stage, said Dr. Larry Puls, the director of gynecologic oncology at Prisma Health Cancer Institute.
Only 10% to 15% of them will survive long-term. And overall survival numbers haven’t changed much in 40 years, he said.
Though blood work can test for a protein that can identify some ovarian cancers, only half of stage 1 patients test positive for it, Puls said.
“One of the things that has eluded us in ovarian cancer is that we have no screening for it,” he said. “But if you can find it when it’s confined to just the ovary alone, 90% of patients beat their cancer.
“If we could shift women out of stage 3 and into stage 1,” he added, “we can make a huge impact on this disease.”
For some time, Bruce has been studying exosomes, which are microscopic droplets found in body fluids that were traditionally regarded as a way for cells to rid themselves of debris.
But further research revealed that they contain parts of the cell they are from as well as proteins that can serve as biomarkers of what’s going on in that cell, she said.
Cancer often develops because something goes awry in the DNA, leading to aberrant proteins and tumor growth, she said. So she theorized that finding those protein signatures in exosomes could be a way to diagnose cancer.
“If we can find those aberrant protein signatures and see them on the cells and exosomes,” she said, “ ... it potentially could be used for any type of cancer, as long as you find the biomarker.”
The process has the potential to be used as a diagnostic tool for other diseases as well, she said.
So Bruce approached Clemson chemistry professor Ken Marcus, who’d been separating whole human cells for years using fiber strips, and asked if he could separate exosomes.
“I said, ‘I don’t even know what they are,’ ” he recalls with a chuckle.
“But she got us some samples and in pretty short order ... we made some really good educated guesses and it worked.”
Marcus and his “very talented students” were not only able to separate the exosomes, but reduced the time needed to do it from 2 1 / 2 hours to 8 min utes using a test strip made of a polymer that is grooved much like the top of a zip lock bag.
When fluid is added, it flows down the channels where it interacts with different antibodies that in turn isolate the exosomes, he said, much the way a pregnancy test works.
Catching it early
Bruce and Marcus were then introduced to Puls, who joined the research team.
He’s collecting samples of cervical fluid containing exosomes and proteins obtained at the same time as a pap test. So far, 49 women have been tested with the strip, Puls said, and two who had no symptoms and normal blood tests were revealed to have stage 1 ovarian cancer.
“That’s the patient we covet the most because we cure 90% of those patients,” he said.
Puls also hopes the test will one day detect precancerous changes, enabling doctors to surgically remove the tissue — like they do when a pap test reveals a precancerous change — and prevent the development of cancer in the first place.
While the initial data will be crunched in the next few weeks, Puls said he’s optimistic that the test could be a promising new tool in the battle against ovarian cancer.
He hopes the test could be used to screen for uterine cancer as well, which strikes another 63,000 women a year.
The Holy Grail for the process, Marcus said, would be a urine test because it can show what’s going on inside the whole body. But the first step is testing cervical fluid in the doctor’s office.
“And even that is an infinite step up from where we are today,” he said.
Because tumors can be caused by a variety of proteins, the test will look for a bank of markers in an effort to capture more cancers, said Bruce, who is also director of Clemson’s Light Imaging Facility.
“I think we’re close on getting some kind of screening tool,” she said. “And we’re in the process now of (getting) all the patents.”
So far, the research has been privately funded, but the team plans to use their initial data to apply for federal grants to continue their work.
They estimate a test could be ready for market in about five years.
Carmen Brotherton hopes the test will be routine in her daughter and grand-daughters’ lifetimes.
The Easley woman’s ovarian cancer was discovered in 2009, making her one of the few to be diagnosed in stage 1.
“I’ve lost some good friends ... who weren’t caught in time,” said Brotherton, who volunteers with the South Carolina Ovarian Cancer Foundation.
“It’s always been one of my prayers that some day they would come up with something that would catch it,” she said.
“This is just a small place compared to the U.S. or the rest of the world. Imagine how many women this could catch. And it might save their lives.”
When Bruce’s brother was diagnosed in 2012, little could be done to stop the progress of the cancer, she said. He died in January, leaving his two sons fatherless.
Now she hopes the test will one day mean that fewer people will be left without a parent like her nephews.
“In conjunction with the discovery of distinct biomarkers, the fibers could lead to finding diseases such as ovarian cancer — and brain cancer — much earlier,” she said.
“Early enough, I hope, to save many lives in the future.”
Top life sciences leaders from across the state have been named to the SCBIO Executive Committee see more
Leadership team provides strategic blend of economic development, industry, higher education expertise
GREENVILLE, SC – January 17, 2019 – SCBIO has announced its 2019 Executive Committee following formal confirmation at the life science organization’s December 2018 meeting in Columbia. Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve a second term as SCBIO’s 2019 Board Chair.
Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by more than 300% and increased shipped product to one billion doses each of the last seven years. Nephron constructed a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy. The organization was honored as an inaugural winner of the South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry in October, 2018.
Joining Ms. Kennedy on the SCBIO Executive Committee will be Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Vice Chair; Michael Rusnak, Executive Director of the MUSC Foundation for Research Development as Treasurer; and Josh Ridley, Global Business Development Director of ZEUS as Secretary.
Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Heather Simmons Jones, CEO of the Greenwood Partnership Alliance as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; Adam Hoots, Life Sciences Market Leader for DPR Construction as Talent/Workforce Officer; and Sam Konduros, President and CEO of SCBIO.
Recognized for completing their terms as contributing members of the SCBIO Executive Committee were former Vice Chair Craig Walker, executive with Hitachi Healthcare Americas, and former Secretary Kathryn Becker, Principal with Translational Science Solutions LLC.
SCBIO President and CEO Konduros praised the Executive Committee noting, “With the critically important efforts we are undertaking to advance pharmaceuticals, life sciences R&D, biotech, med-tech, and the health IT industries in South Carolina, we require strong, expert leadership from across the state, fully integrating our business, education and economic development sectors. These diverse leaders who represent the width and breadth of our state and industry will effectively champion our vision of building the business of life sciences in South Carolina for years to come.”
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.
The Executive Committee and Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.
SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations. SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.
For additional information on SCBIO, visit www.SCBIO.org.
Medical device manufacturer launching new operations in the Upstate; life science boom continues see more
Medical device manufacturer launching new operations in the Upstate
Monday, October 16, 2017
COLUMBIA, S.C. – Arthrex, Inc., a global orthopedic medical device company, headquartered in Naples, Fla., is launching new manufacturing operations in Anderson County. The $69 million capital investment is expected to create more than 1,000 new jobs over the next several years.
With a corporate mission aimed at helping surgeons treat patients better, Arthrex is a leader in new product development and medical education in orthopedics. The company is a pioneer in the field of arthroscopy and has developed more than 11,000 innovative products and surgical procedures to advance minimally invasive orthopedics worldwide.
Located at 5500 Highway 76 in Sandy Springs, S.C., Arthrex will be constructing a new 200,000-square-foot facility to manufacture its innovative orthopedic devices and implants. Hiring for the new positions should begin in the next 12 to 18 months, and interested applicants should visit the company’s careers page online(link is external).
The Coordinating Council for Economic Development has approved job development credits related to this project.
“Arthrex is pleased to bring its innovative spirit and unique culture to Anderson County, S.C. and we look forward to leveraging the outstanding work done in the area to prepare future employees for high-level manufacturing jobs.” –Arthrex Vice President of Manufacturing Andy Owen
“South Carolina’s business-friendly climate continues to attract companies in every industry, and we’re proud to welcome Arthrex, Inc. to our growing business community. This a milestone for Anderson County, and we can’t wait to see the difference these jobs will make in the region.” –Gov. Henry McMaster
“Not only does our state excel in manufacturing, we’re also increasingly becoming a top choice for companies in the life sciences sector. Arthrex joins an impressive roster of life sciences firms that call South Carolina home, and we look forward to watching them grow in Anderson County for years to come.” –Secretary of Commerce Bobby Hitt
“We are absolutely thrilled to begin our partnership with Arthrex. Their precision medical products are used by medical professionals around the globe, and the fact that our citizens have been chosen to make them says volumes about the quality of our workforce as well as the skills training we provide.” –Anderson County Council Chairman Tommy Dunn
“This announcement takes our county in an exciting direction. Our goal of establishing a diverse economic base for our citizens is becoming a reality. The presence of this world-class company in our community speaks for who we are in Anderson, and we welcome them with open arms.” –Anderson County Councilman Tom Allen, District Four
FIVE FAST FACTS
- Arthrex is launching new manufacturing operations in Anderson County.
- $69 million capital investment to create more than 1,000 new jobs.
- Arthrex is a leading manufacturer of orthopedic medical devices.
- Located at 5500 Highway 76 in Sandy Springs, S.C., the company will be constructing a new 200,000-square-foot facility to manufacture its innovative orthopedic devices and implants.
- Hiring for the new positions should begin in the next 12 to 18 months, and interested applicants should visit the company’s careers page online.
Building the business of life sciences in South Carolina has become the call to action of SCBIO... see more
Building the business of life sciences in South Carolina has become the call to action and theme of the 2017 annual conference of the S.C. Biotechnology Organization (SCBIO). The rapidly evolving statewide industry association is featured in this September 2017 issue of Charleston Business Magazine, and will be featured in October 2017 issues of Columbia Business and Greenville Business as well. Click here for the full article.
SCRA Collaboration Center Awards feature numerous life science organizations from across the state. see more
South Carolina Research Authority’s SCRA-Academia Collaboration Team announces nearly $600,000 in feasibility grants for six projects. The awarded projects encourage collaboration between academic institutions and industry partners to advance commercially relevant research and establish the feasibility of the formation of Collaboration Centers. These Collaboration Centers will be founded for those areas demonstrating a critical mass of talent, infrastructure, financial resources, intellectual property and the prevalence of industry in South Carolina.
“These Feasibility Grants are the first step in establishing Collaboration Centers, which will garner national recognition for South Carolina, create jobs, engage industry and have an overall positive impact on the state.” said Christine Dixon Thiesing, Director of Academic Programs. “SCRA is fostering the growth of collaboration across academic institutions and between academia and industry through the support of six innovation projects.”
The Feasibility Grant Awards are the result of the efforts of the SACT, which was formed to deliver outcomes aligned with the Strategic Collaboration Agreement signed by SCRA and the presidents of the state’s research universities. The SACT is composed of representatives from the research universities, comprehensive teaching institutions, technical colleges, industry and SCRA. The SACT is currently evaluating the feasibility of establishing three Collaboration Centers – a Composites Industry Solutions Center, Medical Devices Collaboration Center, and Technology-Enabled Population Health Collaboration Center.
The list of grant awardees is below:
Composites Industry Solutions Center:
Collaboration among Clemson University, Greenville Technical College and industry partners Kistler Instrument Corp., Keyence Corporation of America and Renishaw.
Medical Devices Collaboration Center:
Collaboration between the Medical University of South Carolina and Clemson University.
Technology-Enabled Population Health Collaboration Center:
Collaboration among the Medical University of South Carolina, Trident Technical College and industry partners Zeriscope, Inc. and Amanda Senior Care.
Collaboration between Francis Marion University and a regional health organization as the industry partner.
Collaboration among University of South Carolina – Upstate and industry partners ChartSpan Medical Technologies and a state agency.
Collaboration among Clemson University, Florence-Darlington Technical College’s Southeastern Institute of Manufacturing and Technology and industry partner Greenville Health System.
ZEUS Industrial has acquired MWC Technologies, LLC see more
ORANGEBURG, S.C., June 11, 2018 -- Zeus Industrial Products, Inc. (Zeus), a leading polymer extrusion manufacturer and material science innovator, today announced that it has acquired MWC Technologies, LLC (MWC). This adds to the capabilities that Zeus has been developing for the past five decades.
MWC, a manufacturer of medical device components based in Chattanooga, TN, possesses innovative technologies that support Zeus' growth strategy. This acquisition will allow for the global commercialization of the many cutting-edge, solution-driven products in MWC's portfolio.
Click to Tweet: @ZeusTubing acquires MWC Technologies: https://www.zeusinc.com/2018/06/11/zeus-acquires-mwc-technologies-llc/
"Since I founded the company in 1966, Zeus has been focused on continuing to grow and innovate. This acquisition supports those goals. We are confident that our acquisition of MWC will provide value to our customers today and into the future.." – Frank P. Tourville, Sr., Founder and Chairman of the Board, Zeus Industrial Products, Inc.
"The acquisition of MWC will expand our capabilities and product portfolio to address the rising demand for advanced precision extrusions. Our combined expertise will enhance our ability to better serve customers around the globe." – John Winarchick, CEO, Zeus Industrial Products, Inc.
"We are excited to be joining the Zeus team! Zeus's long term commitment to industry leading quality, customer service and innovation aligns well with MWC's culture. Our combined technologies will enable new to the market solutions for our customers." – Eric Avans, Quality Manager, MWC Technologies
Zeus Industrial Products: Learn more about the company and its products on the Zeus website; or call toll-free 1-800-526-3842 or +1-803-268-9500 outside the U.S.
ABOUT ZEUS INDUSTRIAL PRODUCTS, INC.
Zeus Industrial Products, Inc., is headquartered in Orangeburg, SC, USA. Its core business is the development and precision extrusion of advanced polymeric materials. The company employs over 1,500 people worldwide with manufacturing facilities in Aiken, Gaston and Orangeburg, South Carolina; Branchburg, New Jersey; and Letterkenny, Ireland. Zeus products and services serve companies in the medical, automotive, aerospace, fiber optics, energy and fluid management markets. For more information, visit www.zeusinc.com.
John Osborne honored by Charleston Southern University see more
CHARLESTON, S.C. – Charleston Southern University presented the Distinguished Service Award to John Osborne, a successful Charleston entrepreneur, at commencement ceremonies Saturday, May 5 at North Charleston Coliseum.
Osborne is the executive administrator of Charleston Angel Partners, director of The Harbor Entrepreneur Center and managing partner of Good Growth Capital. In addition, he has a background in the financial services industry in commercial banking, private banking and wealth management with First Citizens Bank, Regions Bank, Bank of America and MassMutual. Osborne also serves as a member of the Industry and Innovation Council of SCBIO, South Carolina's life sciences industry organization. The Harbor Entrepreneur Center hosts SCBIO's Charleston office onsite.
He received a bachelor of science in finance and economics from Charleston Southern in 2002 and played on the CSU men’s golf team for four years.
“CSU provided a great foundation in my chosen major of finance and economics to build from as I continue to grow businesses which also support economic development efforts in our region,” said Osborne. “My involvement in startups stems from a combination of genuinely caring about seeing people pursue their passions and a recognition of the need for a more systematic way to connect people with resources to those who need them. It’s been a lifelong journey which is still evolving.”
President Jairy C. Hunter Jr. said, “John always exhibits strong leadership skills and a willingness to help others. John is a superb example of a servant business leader. He is humble, intelligent and committed to helping entrepreneurs be successful in their business ventures. We are blessed that John chose to attend CSU. He was an excellent golfer and student. ”
Osborne said, “To be recognized for service to the community, which is something I am passionate about, by CSU is a humbling honor for which I am grateful.”
Osborne is a 2008 graduate of Leadership Charleston. He is currently serving on the West Ashley Revitalization Commission, the South Carolina Innovation Advisory Council, and is a founding member of the Start Up Champions Network. He has been recognized by Charleston Regional Business Journal as a 40 under 40; by Azalea Magazine as Visionary of the Year, and was named to Charlie Magazine’s 50 Most Progressive.
He has been on the Board of Directors for Charleston Metro Chamber of Commerce, The Education Foundation, The Charleston International Film Festival and The Harbor Entrepreneur Center.
Osborne and his wife, Allison, have two sons.
ZEUS promotes Steve Peterson to President see more
Steve Peterson has been named president of SCBIO investor group Zeus Industrial Products Inc., a polymer extrusion manufacturer and material science innovation company based in Orangeburg, effective immediately.
Peterson previously held the position of global head of marketing and sales and senior vice president. He will continue to report to Zeus CEO John Winarchick.
“Since joining Zeus in 2017, Steve has been leading the global sales and marketing function,” Winarchick said in a news release. “During this time, he has demonstrated exceptional customer focus and leadership. Along with his ample skill set and experience, these capabilities will prove extremely valuable in his new role.”
Peterson will focus on developing growth strategies and team building.
"I look forward to leading our 1,500-plus employees around the globe as we continue to deliver top-notch service to our customers,” Peterson said. “I will focus on maintaining the growth momentum Zeus has enjoyed since its inception. I am grateful for the confidence placed in me and am excited to assume this new role.”
Personalized approaches to treating autism spectrum disorder advance... see more
The Greenwood Genetic Center and Swiss biotechnology innovator, Stalicla, have signed a research agreement to collaborate on personalized approaches to treating autism spectrum disorder, or ASD. Stalicla has developed an algorithm platform based on big data to bring precision medicine to subtypes of autism spectrum disorder patients, according to a news release.
“Over the past 10 years, evidence has accumulated pointing toward alterations in molecular pathways that lead to abnormal cell functioning in ASD,” said Lynn Durham, CEO of Geneva-based Stalicla, in the release. “At Stalicla, we are looking to bring disease-modifying personalized medicine to patients with ASD, one subgroup after the other.”
South Carolina Commerce awards $700K in innovation grants... see more
Nine organizations receive state funds as part of Startup Fuel Challenge
The S.C. Department of Commerce Office of Innovation announced more than $719,000 in grant awards to nine organizations as part of its Startup Fuel Challenge grant series. Tasked with advancing innovation, entrepreneurship and technology-based economic development, this grant program focuses on projects that are outcome-oriented and aim to build stronger entrepreneurs and companies.
“As South Carolina has become a leader in advanced manufacturing, an innovation economy has developed within our borders. To ensure that our industry partners have access to cutting-edge technology and a high-tech workforce, the continued growth of our innovation economy is critical,” said Secretary of Commerce Bobby Hitt. “I congratulate these nine awardees and look forward to all they’ll achieve in the years to come.”
Established in 2013, the Office of Innovation announced grant awards in 2014 and 2015. As a result, more than 25 entrepreneurship programs were supported, and more than 6,000 South Carolinians were educated in technology curriculum.
A cardiac technologist in South Carolina has invented a solution to catheter-associated UTIs see more
James Conner, a cardiac technologist at Bon Secours St. Francis Health System in Greenville, SC has invented a device that alerts health care providers at the first sign of hospital-acquired infection caused by urinary catheters. Read full story...
MED-ALLY is growing! The organization is locating new operations in South Carolina... see more
COLUMBIA, S.C. – MED-ALLY, a privately-held medical device manufacturer, is locating new operations in Berkeley County. The $2.38 million investment is expected to create 90 new jobs.
MED-ALLY is an innovative design, development and manufacturing company specializing in active implantable medical systems. The company has designed and developed VersaStim® neuromodulation platform technology, which treats patients with movement disorders, spinal cord injuries, chronic pain and traumatic brain injuries. The VersaStim® technology platform is available in external and implantable systems for clinicians to maximize therapy effectiveness and improve patient outcomes.
The company’s state-of-the-art, 10,000-square-foot manufacturing operation will be located in the Charleston International Manufacturing Center at 2040 Bushy Park Road in Goose Creek, S.C. An ISO Class 6 Clean Room, critical for the fabrication of implantable devices, will take up approximately half of the operating space. Expected to be fully operational in March 2018, MED-ALLY is already hiring for its new technical positions. Those interested in joining the team should visit www.med-ally.com(link is external).
The Coordinating Council for Economic Development has approved job development credits related to this project.
“We are indeed fortunate for the opportunity to join the many successful and class-leading companies that call the Lowcountry and Charleston home, and can only aspire to one day approach a close enough level of similar lofty accomplishments! Through the professional South Carolina organizations and wonderful associates at every level at the CRDA, SCRA, SCBIO, S.C. Commerce and others, more akin to treasured business partners over all else, we believe that we are surrounding ourselves with an enabling, empowering and conducive team like no other. We look forward to growing and prospering in Berkeley County amidst its wonderful constituency and leadership team.” –MED-ALLY, LLC CEO and Co-Founder Raja Edward Hitti
“We are excited to join the growing South Carolina medical device community and deliver innovative bioelectronic products that positively impact the global Healthcare market. The MED-ALLY team is looking forward to working with distinguished clinicians, university medical teams, industry partners and university students dedicated to providing disruptive medical device solutions to treat debilitated patients worldwide.” –MED-ALLY, LLC President and Co-Founder John Mulvihill
“It’s always exciting when a company decides to locate new operations in South Carolina, and we’re pleased to welcome such an innovative firm that’s focused on cutting-edge advanced manufacturing. I congratulate them on this new investment and can’t wait to see what the future has in store for them here.” –Gov. Henry McMaster
“The life sciences industry is one that presents significant growth opportunities for South Carolina, and today’s announcement by MED-ALLY is proof of that. I congratulate this innovative company and wish them much success in the Lowcountry.” –Secretary of Commerce Bobby Hitt
“MED-ALLY’s announcement of its medical device manufacturing project in the Lowcountry is extremely exciting for Berkeley County; we are honored to welcome MED-ALLY, their investment and the 90 technical jobs they offer. MED-ALLY’s announcement is also further proof that Berkeley County is open for business, and Berkeley County means business. Through meetings with the company’s team, I am confident MED-ALLY will thrive in Berkeley County and also be incredible partners in job creation opportunities for many years to come.” –Berkeley County Supervisor Bill Peagler
“We’ve been talking with MED-ALLY for some time about the competitive advantages the Charleston region offers, and we’re thrilled our community successfully competed against much larger U.S. metros to attract this implantable medical device manufacturer to locate its headquarters, R&D and manufacturing facility in Berkeley County. We are proud to welcome MED-ALLY to Charleston’s growing life sciences cluster. They will be a tremendous asset for many years to come.” –Charleston Regional Development Alliance Chairman Will Helmly
FIVE FAST FACTS
- MED-ALLY is locating new manufacturing operations in Berkeley County.
- $2.38 million investment to create 90 new jobs.
- MED-ALLY is a personalized health solutions company dedicated to manufacturing medical devices.
- Located at 2040 Bushy Park Road in Goose Creek, S.C., the company’s new facility is projected to be operational in March 2018.
- Those interested in joining the MED-ALLY team should visit www.med-ally.com(link is external).